title: Bimonthly ranibizumab for neovascular age-related macular degeneration.
abstract: OBJECTIVE
  Recently, aflibercept was proposed with a protocol of a bimonthly fixed regimen. Our purpose was to evaluate the results of this regimen in patients treated with ranibizumab.
  
  
  METHODS
  We conducted a retrospective analysis of consecutive patients with naïve neovascular age-related macular degeneration treated with a bimonthly fixed regimen of intravitreal injections of ranibizumab after 3 monthly injections. Examination was performed every 4 weeks for 52 weeks, with the possibility of unscheduled rescue injections of ranibizumab.
  
  
  RESULTS
  A total of 27 patients, 24 women and 3 men, aged from 68 to 90 years (mean: 81.2) were analyzed; 25 eyes (92.5%) lost <15 letters. Mean BCVA rose from 58.3 (range ± 12.9) to 66.7 (range ± 14.3) letters. The mean visual gain was 8.40 (range ± 13.2) letters; 11 patients (40.7%) gained ≥ 15 letters. The mean number of injections of ranibizumab was 8.77.
  
  
  CONCLUSIONS
  Bimonthly intravitreal ranibizumab achieved satisfactory visual results. However, patients who required additional injections did not experience significant visual gain.
authors.affiliation: Centre Ophtalmologique d'Imagerie et de Laser, Paris, France.
authors.forename: Salomon Yves
authors.initials: SY
authors.lastname: Cohen
authors.forename: Bertrand
authors.initials: B
authors.lastname: Maloberti
authors.forename: Franck
authors.initials: F
authors.lastname: Fajnkuchen
authors.forename: Sylvia
authors.initials: S
authors.lastname: Nghiem-Buffet
authors.forename: Corinne
authors.initials: C
authors.lastname: Delahaye-Mazza
authors.forename: Typhaine
authors.initials: T
authors.lastname: Grenet
authors.forename: Gabriel
authors.initials: G
authors.lastname: Quentel
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage*; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D005260:Female; D005451:Fluorescein Angiography; D005500:Follow-Up Studies; D005654:Fundus Oculi; D006801:Humans; D058449:Intravitreal Injections; D008268:Macular Degeneration / Q000150:complications / Q000188:drug therapy* / Q000473:pathology; D008297:Male; D000069579:Ranibizumab; D015861:Retinal Neovascularization / Q000150:complications / Q000188:drug therapy* / Q000473:pathology; D012189:Retrospective Studies; D016896:Treatment Outcome; D014792:Visual Acuity
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D000069579:Ranibizumab